Resazurin Microtiter Assay Plate method for detection of susceptibility of multidrug resistant Mycobacterium tuberculosis to second-line anti-tuberculous drugs  by Khalifa, Reham A. et al.
Egyptian Journal of Chest Diseases and Tuberculosis (2013) 62, 241–247The Egyptian Society of Chest Diseases and Tuberculosis
Egyptian Journal of Chest Diseases and Tuberculosis
www.elsevier.com/locate/ejcdt
www.sciencedirect.comORIGINAL ARTICLEResazurin Microtiter Assay Plate method for detection of
susceptibility of multidrug resistant Mycobacterium
tuberculosis to second-line anti-tuberculous drugsReham A. Khalifa a, Marwa S. Nasser a, Ashraf A. Gomaa b, Nehad M. Osman b,*,
Hala M. Salem ba Medical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Egypt
b Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, EgyptReceived 12 April 2013; accepted 14 May 2013
Available online 12 June 2013*
E-
Pe
D
04
OpKEYWORDS
Mycobacterium tuberculosis
(M. tuberculosis);
Minimal inhibitory concen-
tration (MIC) evaluation;
Resazurin;
Second-line anti tuberculous
drugsCorresponding author.
mail address: Osman_Nehad
er review under responsibil
iseases and Tuberculosis
Production an
22-7638 ª 2013 The Egyptia
en access under CC BY-NC-ND li@yahoo.
ity of Th
d hostin
n Society
httpcense.Abstract Background: Many developed countries need a diagnostic test that is accurate, rapid,
and economical in detecting multidrug-resistant tuberculosis. This study aims to evaluate Resazurin
Microtiter Assay Plate in detecting susceptibilities of multidrug resistant Mycobacterium tuberculo-
sis to second line anti tuberculous drugs.
Methods: Susceptibility of multidrug resistant M. tuberculosis was evaluated against 5 second
line anti tuberculous drugs by the colorimetric method using the Resazurin Microtiter Assay Plate
Testing (REMA).
Results: Drug susceptibility testing for the second-line drugs was performed for 34 MDR M.
tuberculosis isolates isolated from 40 sputum samples. Results of REMA were available after 8 days
of incubation. The agreement between the two tests for para-aminosalicylic acid, ethionamide, oﬂox-
acin, kanamycin monosulfate and cycloserine was found to be 97.05%, 94.11%, 97.05%, 97.05% and
100%, respectively. The efﬁcacy of REMA plate assay for PAS, ETH, OFX, KAN and CYL was
97.05%, 94.11%, 97.05%, 97.05% and 100%, respectively.
Conclusion: Resazurin test was found to be reliable, simple to perform for the rapid detection of
anti-tuberculous drug resistance and economically inexpensive.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
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Tuberculosis remains an important public health problem and
has recently been increasing in incidence [1]. Tuberculosis (TB)
is a serious public health problem in many developing coun-
tries, According to the World Health Organization (WHO) re-
port in 2005, there were 8.8 million new TB Cases and 1.6
million deaths were attributed to the disease worldwide [2].is. Production and hosting by Elsevier B.V.
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242 R.A. Khalifa et al.Egypt is ranked as a country with middle/low level of tubercu-
losis (TB) incidence. It is estimated that 11 cases per 100,000
population develop active pulmonary smear positive TB annu-
ally, while 24 per 100,000 develop all types of TB annually
according to the World Health Organization (WHO) report
in 2010 [3]. Multidrug resistant (MDR) Mycobacterium tuber-
culosis strains have been observed around the world, with high
mortality rates particularly among HIV-positive patients [4–6].
MDR TB is now also emerging in HIV-negative populations
and in high-risk populations such as medical staff [7,8].
MDR M. tuberculosis isolates present a major challenge for
tuberculosis control programs [9]. Although progress has been
made to reduce global incidence of drug-susceptible tuberculo-
sis, the emergence of MDR and extensively drug-resistant
(XDR) tuberculosis during the past decade threatens to under-
mine these advances. However, countries are responding far
too slowly. Of the estimated 440,000 cases of MDR tuberculo-
sis that occurred in 2008, only 7% were identiﬁed and reported
to WHO. Of these cases, only a ﬁfth were treated according to
WHO standards [10]. MDRTB patients do not respond to
treatment with the ﬁrst-line drugs isoniazid (INH), rifampin
(RIF), ethambutol (EMB), pyrazinamide (Z) and streptomycin
(SM) [11–14].Consequently, the treatment of MDR-TB in-
volves the use of reserve drugs called ‘second-line drugs’ [15].
Several studies have shown that MDR TB can be cured by a
combination of second-line drugs under DOTS-Plus, the treat-
ment strategy proposed by the World Health Organization to
address the management of MDR TB in settings with good
control programs [14–19]. However, these drugs are expensive,
have to be taken for long periods, and can cause adverse reac-
tions [14]. Rapid diagnosis of MDR patients is nevertheless
necessary to avoid the spread of MDR strains. Therefore,
microbial susceptibility should be ascertained to diagnose
MDR tuberculosis. The test should be speciﬁc, inexpensive, ra-
pid, simple and applicable to developing countries [20]. The
conventional agar and Lo¨wenstein–Jensen (LJ) proportion
method is laborious, with results only available after 3–
6 weeks. The BACTEC radiometric system (Becton Dickinson)
had the advantage of being more rapid than the proportion
method, but required the use of radioisotopes, which was a dis-
advantage with respect to the disposal of waste materials and
was expensive to perform [21,22]. In recent years, several
new methods have been proposed for the rapid performance
of Drug susceptibility testing (DST) ofM. tuberculosis, includ-
ing phage assays [23] and cytoﬂuorometry [24,25].
The development of new, rapid Drug susceptibility testing
which is easy to use and inexpensive is thus an urgent priority
for determining the susceptibility to second line drugs [26,27].
A new method using the oxidation–reduction colorimetric
indicator resazurin has been proposed for the determination
of drug resistance and minimal inhibitory concentration
(MICs) of antimicrobial agents against M. tuberculosis [28–
31]. Resazurin, which is blue in its oxidized state, turns pink
when reduced by viable cells. The REMA plate method has
been described for MIC determination of M. tuberculosis clin-
ical isolates and has been tested successfully against INH and
RIF for the detection of MDRTB [28,32,33].
Aim of this work
The study evaluated Resazurin Microtiter Assay Plate in the
detection of susceptibilities of MDR M. tuberculosis tosecond-line anti-tuberculous drugs. The results were compared
to those obtained by the standard proportional method (PM)
performed on Lo¨wenstein–Jensen medium (LJ).Subjects and methods
Patients
Forty patients (28 males and 12 females) suffering from multi-
ple drug resistant pulmonary tuberculosis (MDR) with age
ranging from 20 to 62 years, who attended MDR ward at
Abbassia chest hospital in the period from December 2011
to April 2012 were chosen for the study.
Methods
Susceptibility of multidrug resistantM. tuberculosis was evalu-
ated against 5 second-line anti-tuberculous drugs: ethionamide
(ETH), kanamycin monosulfate (KAN), cycloserine (CYL),
oﬂoxacin (OFX), and para-aminosalicylic acid (PAS) by the
colorimetric method using the REMA Plate Testing and the re-
sults were compared to those obtained using the proportional
method (PM), considered as the gold standard. All sputum
specimens were digested and decontaminated of other bacteria
by the standard N-acetyl-L-cysteine–NaOH–sodium citrate
method followed by centrifugation and concentration accord-
ing to Kubica et al. [34], then cultured on LJ medium. Six sam-
ples yielded negative cultures and 34 isolates were identiﬁed by
niacin accumulation test (Becton Dickinson, USA), growth
inhibition by thiophene-2-carboxylic acid hydrazide (Sigma–
Aldrich, USA) and pyrazinamidase test (Himedia, India).
ETH, OFX, CYL, KAN and PAS were obtained from Sigma
Aldrich, India. Stock solutions at 1 mg/ml were ﬁlter sterilized
and stored at 20 C. Working solutions were prepared at
four times the ﬁnal higher concentration in 7H9-S broth (Mid-
dlebrook 7H9 supplemented with 0.1% Casitone, 0.5% glyc-
erol, and 10% OADC [oleic acid, albumin, dextrose, and
catalase]; Becton–Dickinson). The ﬁnal drug concentrations
tested were as follows: for PAS and OFX, 8 lg/ml; for ETH
and KAN and CYL, 20 lg/ml. A stock solution of resazurin
sodium salt powder (Sigma Aldrich, China) was prepared at
0.02% (wt/vol) in distilled water, sterilized by ﬁltration, and
stored at 4 C for up to 1 week. The inoculum was prepared
from fresh LJ medium in 7H9-S broth, adjusted spectrophoto-
metrically to a no. 1 McFarland tube standard, and further di-
luted 1:10 in 7H9-S broth for the test. The REMA plate assay
(Fig. 1) was performed according to Taneja and Tyagi [35] and
Martin et al. [36]. Brieﬂy, 100 ll of 7H9-S broth was dispensed
in each well of a sterile ﬂat-bottom 96-well plate (Becton Dick-
inson, USA) and serial two fold dilutions of each drug were
prepared directly in the plate. One hundred microliters of inoc-
ulum was added to each well (2 isolates per plate). A growth
control and a sterile control were also included for each isolate.
Sterile water was added to all perimeter wells to avoid evapo-
ration during the incubation. The plate was covered, sealed in
a plastic bag, and incubated at 37 C under a normal atmo-
sphere. After 7 days of incubation, 30 ll of resazurin solution
was added to each well, and the plate was re-incubated over-
night. A change from blue to pink indicates reduction of resa-
zurin and therefore bacterial growth. A change in color from
blue to pink indicated the growth of bacteria, and the minimal
Figure 1 REMA plate assay for 4 isolates: isolate (a) with MIC
10 lg/ml for ETH, isolate (b) with MIC 20 lg/ml for KAN, isolate
(c) with MIC 20 lg/ml for ETH and isolate (d) sensitive.
Table 1 MICs of ﬁve second-line drugs for resistant isolates
detected by REMA plate method:
REMA results
Drug MIC (lg/ml) Number of isolates
PAS 4 2
8 1
Total 3
ETH 5 7
10 3
20 2
Total 12
OFX 4 3
8 2
Total 5
KAN 5 4
10 1
Total 5
CYL 5 1
20 1
Total 2
Resazurin microtiter assay plate method 243inhibitory concentration (MIC) was deﬁned as the lowest con-
centration of the drug that prevented this change in color. A
change in color of growth control well to pink indicated the
proper growth of the isolate and no change in color of sterile
control well indicated absence of contaminants. The drug con-
centration ranges used were as follows: 20–0.62 lg/ml for
ETH, KAN and CYL and 8–0.25 lg/ml for OFX and PAS.
Drug cut-off points by REMA were: 2.5 lg/ml for ETH,
CYL and KAN and 2 lg/ml for OFX and PAS [37]. PM
was performed on the LJ medium according to laboratory’s
standard procedure [38] using critical concentration of drugs
mentioned above.
Statistical methods
IBM SPSS statistics (V. 21.0, IBM Corp., USA, 2012) was
used for data analysis. Data were expressed as both number
and percentage for categorized data. Diagnostic validity test
was performed and included: the diagnostic sensitivity {the
percentage of resistant cases truly diagnosed (TP) among totalresistant cases (TP + FN)}, the diagnostic speciﬁcity {the per-
centage of susceptible cases truly excluded by the test (TN)
among total susceptible cases (TN + FP)} and the efﬁcacy
or the diagnostic accuracy of the test {the percentage of resis-
tant cases truly diagnosed plus susceptible cases truly excluded
by the test among total cases}.
TP (true positive), FN (false negative), FP (false positi-
ve).TN (true negative).
Results
DST for the second-line drugs OFX, KAN, CYL, ETH, and
PAS was performed for 34 MDR M. tuberculosis isolates iso-
lated from 40 sputum samples. Results of REMA were avail-
able after 8 days of incubation, while those of testing by the
PM were available after 3–4 weeks. The DST results for the
second-line drugs obtained by PM were as follows: 4 isolate
(11.7%) were resistant to PAS, 14 (41.1%) were resistant to
ETH, 6 (17.6%) were resistant to OFX, 4 (11.7%) were resis-
tant to KAN, and 2 (5.9%) were resistant to CYL. As regards
REMA plate method; number and MICs for ﬁve second-line
drugs of resistant isolates are shown in Table 1.
Table 1 shows that MIC detected by REMA among PAS
resistant isolates (no. = 3) was 4 lg/ml (2 isolates) and 8 lg/
ml (1 isolate). Among ETH resistant isolates (no. = 12) MIC
was 5 lg/ml (7 isolates), 10 lg/ml (3 isolates) and 20 lg/ml (2
isolates). Among OFX resistant isolates (no. = 5), detected
MIC was 4 lg/ml (3 isolates) and 8 lg/ml (2 isolates). For
KAN, MIC of resistant isolates (no. = 5) was 5 lg/ml (4 iso-
lates) and 10 lg/ml (1 isolate). For CYL, MIC of resistant iso-
lates (no. = 2) was 5 lg/ml (1 isolate) and 20 lg/ml (1 isolate).
Table 2 and Fig. 2 show the DST results obtained by the
REMA plate method compared with the PM, considered the
gold standard. For PAS, both methods detected 30 susceptible
isolates and 3 resistant isolates, 1 isolate gave a discrepant re-
sult as resistant by PM while being susceptible by REMA. For
ETH, 20 isolates were detected as susceptible and 12 as
Figure 2 Relation between sensitive and resistant isolates to
second-line drugs detected by REMA & PM.
Table 2 Comparison of results of DST of 34 MDR isolates by PM and REMA plate method.
Drug PM REMA
Number Agreement (%) Sensitivity (%) Speciﬁcity (%) Eﬃcacy (%)
R S Total
PAS R 3 1 4 97.05 75.00 100.00 97.05
S 0 30 30
Total 3 31 34
ETH R 12 2 14 94.11 85.71 100.00 94.11
S 0 20 20
Total 12 22 34
OFX R 5 1 6 97.05 83.33 100.00 97.05
S 0 28 28
Total 5 29 34
KAN R 4 0 4 97.05 100.00 96.67 97.05
S 1 29 30
Total 5 29 34
CYL R 2 0 2 100.00 100.00 100.00 100.00
S 0 32 32
Total 2 32 34
244 R.A. Khalifa et al.resistant by both methods; 2 isolates gave discrepant results as
resistant by PM and susceptible by REMA. For OFX, 5 and 28
isolates were identiﬁed as resistant and susceptible respectively
by both methods while 1 isolate was misidentiﬁed as
susceptible by REMA plate assay. For KAN, 4 isolates were
correctly detected as resistant and 29 as sensitive by both
methods; 1 isolate was false-positive by REMA plate assay.
For CYL, 32 isolates were detected as susceptible and 2 isolates
as resistant by both methods and no discrepant results were
detected.
The agreement between the two tests for PAS, ETH OFX,
KAN and CYL was found to be 97.05%, 94.11%, 97.05%,
97.05% and 100%, respectively. The sensitivity of the REMA
plate assay compared to that of PM was observed to be 75%,
85.71%, 83.33% for PAS, ETH and OFX respectively and
100% for both KAN and CYL. Speciﬁcities were 100% for
PAS, ETH, OFX and CYL and 96.67% for KAN. The efﬁcacyof REMA plate assay for PAS, ETH, OFX, KAN and CYL
was 97.05%, 94.11%, 97.05%, 97.05% and 100%,
respectively.
Discussion
The emergence of drug-resistant M. tuberculosis is a global
concern, the early detection of antimicrobial susceptibility is
especially important for creating an appropriate treatment
protocol for patients with TB [9]. Several studies have stressed
the importance of timely detection of drug resistance in TB
[39].
Laboratories supporting TB services in areas with a high
prevalence of MDR TB must therefore be able to provide
prompt and reliable DST for drugs used in the management
of patients [40]. Preliminary studies of DST of MDR TB iso-
lates using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazo-
lium bromide (MTT), Alamar blue, or resazurin showed a
good correlation with the conventional PM [28,41–45]. The
limitation of some proprietary dyes is the lack of knowledge
of their compositions [46]. Recently, resazurin, a nonpropri-
etary product, has been identiﬁed as the main component of
Alamar blue [47,48]. The REMA plate method has proven to
be, in recent experience, a reliable method for the detection
of MDR TB [28].
The current study was carried upon 40 patients suffering
from MDR TB, DST of 34 M. tuberculosis isolates has been
performed with ﬁve second-line drugs by the REMA plate
method. Results of the REMA plate method were obtained
after 8 days of incubation, while those of testing by the PM
were available after 3–4 weeks. The DST results for the sec-
ond-line drugs obtained by PM were as follows: 4 isolate
(11.7%) were resistant to PAS, 14 (41.1%) were resistant to
ETH, 6 (17.6%) were resistant to OFX, 4 (11.7%) were resis-
tant to KAN, and 2 (5.9%) were resistant to CYL. The REMA
plate method has also shown a high level of agreement with the
conventional PM.
Resazurin microtiter assay plate method 245Results were easily determined visually by reading the
change to a stable color from blue to pink. The agreement be-
tween the two tests for PAS, ETH OFX, KAN and CYL was
found to be 97.05%, 94.11%, 97.05%, 97.05% and 100%,
respectively.
These results conﬁrm recent reports of the performance of
the REMA plate method in other settings. Martin et al. [36]
examined susceptibilities to second-line drugs by using the
REMA Plate Testing and found among the 150 isolates, 31
were resistant to ETH, 29 were resistant to KAN, 9 were resis-
tant to PAS, 8 were resistant to OFX, and 19 were resistant to
CAP by the PM. Complete agreement in results was found for
KAN, PAS, and OFX by the two methods.
The current study showed the sensitivity of the REMA
plate assay compared to that of PM was observed to be
75%, 85.71%, 83.33% for PAS, ETH and OFX respectively
and 100% for both KAN and CYL. Speciﬁcities were 100%
for PAS, ETH, OFX and CYL and 96.67% for KAN. The efﬁ-
cacy of REMA plate assay for PAS, ETH, OFX, KAN and
CYL was 97.05%, 94.11%, 97.05%, 97.05% and 100%,
respectively.
Other studies have reported a higher sensitivity. Martin
et al. [36] found that, among the 150 isolates, the overall
performance of the REMA plate method for the ﬁve antimi-
crobial agents in comparison with that of the PM was very
good. The speciﬁcity was 100% for the ﬁve drugs ethiona-
mide, kanamycin, capreomycin, oﬂoxacin, and para-amino-
salicylic acid, and the sensitivity ranged from 96.8% to
100%; for CAP the sensitivity was 84.2%. The observed dis-
crepancy between these results might be attributed to the lim-
ited number of patients enrolled in the present study and
different geographical distributions. Also these studies in-
cluded different resistant isolates than the present study and
the precision of the sensitivity estimates was accordingly low-
er in this study.
According to the current study REMA was a rapid and an
inexpensive method with all results available in 8 days. REMA
has also the advantage of easily determining the MIC; MIC de-
tected by REMA among PAS resistant isolates (no. = 3) was
4 lg/ml (2 isolates) and 8 lg/ml (1 isolate). Among ETH resis-
tant isolates (no. = 12). MIC was 5 lg/ml (7 isolates), 10 lg/
ml (3 isolates) and 20 lg/ml (2 isolates). Among OFX resistant
isolates (no. = 5), detected MIC was 4 lg/ml (3 isolates) and
8 lg/ml (2 isolates). For KAN, MIC of resistant isolates
(no. = 5) was 5 lg/ml (4 isolates) and 10 lg/ml (1 isolate).
For CYL, MIC of resistant isolates (no. = 2) was 5 lg/ml (1
isolate) and 20 lg/ml (1 isolate).
These results were in accordance with Martin et al. [36] who
reported that the MIC by REMA among PAS resistant iso-
lates (no. = 9) was >8 lg/ml (9 isolate). Among ETH resis-
tant isolates (no. = 31) was 1.25 lg/ml (1 isolates), 5.0 lg/ml
(4 isolates), 10.0 lg/ml (7 isolates) and >20 lg/ml (19 isolates).
Among OFX resistant isolates (no. = 8), detected MIC was
4 lg/ml (4 isolates) and >8 lg/ml (4 isolates). For KAN,
MIC of resistant isolates (no. = 29) was 5 lg/ml (4 isolates),
10 lg/ml (3 isolate) and >20 lg/ml (22 isolates).
The MICs of oﬂoxacin resistant M. tuberculosis isolates
(no. = 8) were determined by Martin et al. [40]. MIC detected
by REMA was 4 lg/ml (5 isolates) and 8 lg/ml (3 isolates). At
2 lg/ml of OFX, the speciﬁcity and sensitivity were both
100%. The results obtained by Martin et al. [40] were in com-plete agreement with those obtained by the PM. Their pro-
posed cutoff value of 2 lg/ml fully agrees with the MIC of pre-
vious study [36].
The microplate format offers many advantages: many
DSTs can be performed at the same time, and the method is
cost effective, including the reagents. It is also rapid and gives
quantitative MIC results.
Umubyeyi et al. [49] reported susceptibility for 120 M.
tuberculosis isolates susceptible to OFX by the BACTEC 460
method, the total of susceptible strains was 106. Of the 120
strains, 14 were resistant with the BACTEC 460 method,
and had a MIC value of 4 lg /ml (8 isolates) and 8 lg/ml (6
isolates) using the REMA method .At 2 lg/ml of OFX, the
speciﬁcity and sensitivity were both 100%. The colorimetric
resazurin assay was found to be an alternative low-cost and ra-
pid method to detect resistance to anti-tuberculosis drug
resistance.
The contribution of TB laboratories worldwide, through
rapid and accurate DST, is very important for the manage-
ment of MDR TB, especially in low-income countries where
most cases of MDR-TB occur.
In this study, the results were obtained after 8 days with
the colorimetric method and are in nearly complete agree-
ment with those obtained by the PM. In a quantitative test
such as REMA, it is also important to establish which of
the concentrations involved in the test will separate suscepti-
ble from resistant strains. The cutoff represents the ‘‘critical
concentration’’ that deﬁnes susceptible and resistant strains
based on the best ﬁt of the colorimetric results with the con-
ventional method.
Our proposed cut-off value for PAS and OFX was 2 lg/ml
and for KAN was 2.5 lg/ml. This is in agreement with the
MIC proposed by Martin et al. [40] and Umubyeyi et al.
[49]. The tentative breakpoint concentration of ETH was
2.5 lg/ml which is in agreement with the MIC proposed by
Martin et al. [36].
Advantages of the micro titer format are being faster, low-
cost and easy to perform and interpret, and does not need spe-
cial equipment or reagent. The cost of the test will vary accord-
ing to the setting and where it is used; however, it compares
favorably with the conventional proportion method in LJ
medium. One disadvantage, however, is biosafety, since the
plates require the use of liquid medium and could generate
aerosols. It has recently been shown that this format can be
adapted for screw-cap tubes to avoid this situation
[41,43,50].This can be overcome by performing the test in indi-
vidual closed tubes; however, the test is recommended for ref-
erence laboratories that already have the necessary biosafety
facilities. Early detection of drug resistance and MDR TB is
very important for adequate control of TB and for starting
the appropriate treatment for the patient. The REMA plate
method appears to be a good alternative method for use in
low-resource countries [51].
Conclusion
Resazurin test was found to be reliable, simple to perform for
the rapid detection of anti-tuberculous drug resistance and
economically inexpensive. It is potentially useful for low-re-
source countries. Therefore, it would be feasible to implement
this method in laboratories with limited resources.
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